Drugs / Fluorestradiol
Fluorestradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01916122 | Aug 2013 → Apr 2024 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorestradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01916122 ↗ |
| Known as | 16α-18F-fluoroestradiol | “A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them.” NCT01916122 ↗ |
| Known as | FES | “A research agent named 16α-18F-fluoroestradiol (FES) finds estrogen receptors and binds to them.” NCT01916122 ↗ |
| Modality | Diagnostic / imaging agent | “can be imaged by a PET/CT scanner” NCT01916122 ↗ |
| Route | Intravenous | “injected intravenously.” NCT01916122 ↗ |